<p>Intratumour heterogeneity and phenotypic plasticity drive tumour progression and therapy resistance<sup><CitationRef CitationID="CR1">1</CitationRef>,<CitationRef CitationID="CR2">2</CitationRef></sup>. Oncogene dosage variation contributes to cell-state transitions and phenotypic heterogeneity<sup><CitationRef CitationID="CR3">3</CitationRef></sup>, thereby providing a substrate for somatic evolution. Nonetheless, the genetic mechanisms underlying phenotypic heterogeneity are still poorly understood. Here we show that extrachromosomal DNA (ecDNA) is a major source of high-level focal amplification in key oncogenes and a major contributor of <i>MYC</i> heterogeneity in pancreatic ductal adenocarcinoma (PDAC). We demonstrate that ecDNAs drive varying levels of <i>MYC</i> dosage, depending on their regulatory landscape, enabling cancer cells to rapidly and reversibly adapt to microenvironmental changes. In the absence of selective pressure, a high ecDNA copy number imposes a substantial fitness cost on PDAC cells. We also show that MYC dosage affects cell morphology and dependence of cancer cells on stromal niche factors. Our work provides a detailed analysis of ecDNAs in PDAC and describes a new genetic mechanism driving <i>MYC</i> heterogeneity in PDAC.</p>

错误:搜索内容不能为空,请输入英文关键词
错误:关键词超出字数限制,请精简
高级检索

MYC ecDNA promotes intratumour heterogeneity and plasticity in PDAC

  • Elena Fiorini,
  • Antonia Malinova,
  • Daniel Schreyer,
  • Davide Pasini,
  • Michele Bevere,
  • Giorgia Alessio,
  • Diego Rosa,
  • Sabrina D’Agosto,
  • Luca Azzolin,
  • Salvatore Milite,
  • Silvia Andreani,
  • Francesca Lupo,
  • Lisa Veghini,
  • Sonia Grimaldi,
  • Serena Pedron,
  • Monica Castellucci,
  • Craig Nourse,
  • Roberto Salvia,
  • Giuseppe Malleo,
  • Andrea Ruzzenente,
  • Alfredo Guglielmi,
  • Michele Milella,
  • Rita T. Lawlor,
  • Claudio Luchini,
  • Antonio Agostini,
  • Carmine Carbone,
  • Christian Pilarsky,
  • Andrea Sottoriva,
  • Aldo Scarpa,
  • David A. Tuveson,
  • Peter Bailey,
  • Vincenzo Corbo

摘要

Intratumour heterogeneity and phenotypic plasticity drive tumour progression and therapy resistance1,2. Oncogene dosage variation contributes to cell-state transitions and phenotypic heterogeneity3, thereby providing a substrate for somatic evolution. Nonetheless, the genetic mechanisms underlying phenotypic heterogeneity are still poorly understood. Here we show that extrachromosomal DNA (ecDNA) is a major source of high-level focal amplification in key oncogenes and a major contributor of MYC heterogeneity in pancreatic ductal adenocarcinoma (PDAC). We demonstrate that ecDNAs drive varying levels of MYC dosage, depending on their regulatory landscape, enabling cancer cells to rapidly and reversibly adapt to microenvironmental changes. In the absence of selective pressure, a high ecDNA copy number imposes a substantial fitness cost on PDAC cells. We also show that MYC dosage affects cell morphology and dependence of cancer cells on stromal niche factors. Our work provides a detailed analysis of ecDNAs in PDAC and describes a new genetic mechanism driving MYC heterogeneity in PDAC.